Rel-deficient	B-cell_type
T	I-cell_type
cells	I-cell_type
exhibit	O
defects	O
in	O
production	O
of	O
interleukin	B-protein
3	I-protein
and	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
.	O

The	O
c-rel	B-DNA
protooncogene	I-DNA
encodes	O
a	O
subunit	O
of	O
the	O
NF-kappa	B-protein
B-like	I-protein
family	I-protein
of	I-protein
transcription	I-protein
factors	I-protein
.	O

Mice	O
lacking	O
Rel	B-protein
are	O
defective	O
in	O
mitogenic	O
activation	O
of	O
B	B-cell_type
and	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
and	O
display	O
impaired	O
humoral	O
immunity	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
changes	O
in	O
gene	O
expression	O
that	O
accompany	O
the	O
T-cell	O
stimulation	O
defects	O
associated	O
with	O
the	O
loss	O
of	O
Rel	B-protein
,	O
we	O
have	O
examined	O
the	O
expression	O
of	O
cell	B-protein
surface	I-protein
activation	I-protein
markers	I-protein
and	O
cytokine	O
production	O
in	O
mitogen-stimulated	O
Rel-/-	B-cell_type
T	I-cell_type
cells	I-cell_type
.	O

The	O
expression	O
of	O
cell	O
surface	O
markers	O
including	O
the	O
interleukin	B-protein
2	I-protein
receptor	I-protein
alpha	I-protein
(	I-protein
IL-2R	I-protein
alpha	I-protein
)	I-protein
chain	I-protein
(	O
CD25	B-protein
)	O
,	O
CD69	B-protein
and	O
L-selectin	B-protein
(	O
CD62	B-protein
)	O
is	O
normal	O
in	O
mitogen-activated	B-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
but	O
cytokine	B-protein
production	O
is	O
impaired	O
.	O

In	O
Rel-/-	B-cell_line
splenic	I-cell_line
T	I-cell_line
cell	I-cell_line
cultures	I-cell_line
stimulated	O
with	O
phorbol	O
12-myristate	O
13-acetate	O
and	O
ionomycin	O
,	O
the	O
levels	O
of	O
IL-3	O
,	O
IL-5	O
,	O
granulocyte-	B-protein
macrophage	I-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
,	O
and	O
gamma	B-protein
interferon	I-protein
(	O
IFN-gamma	B-protein
)	O
were	O
only	O
2-	O
to	O
3-fold	O
lower	O
compared	O
with	O
normal	O
T	O
cells	O
.	O

In	O
contrast	O
,	O
anti-CD3	B-protein
and	O
anti-CD28	B-protein
stimulated	O
Rel-/-	B-cell_line
T	I-cell_line
cells	I-cell_line
,	O
which	O
fail	O
to	O
proliferate	O
,	O
make	O
little	O
or	O
no	O
detectable	O
cytokines	B-protein
.	O

Exogenous	O
IL-2	B-protein
,	O
which	O
restitutes	O
the	O
proliferative	O
response	O
of	O
the	O
anti-CD3-	B-cell_line
and	I-cell_line
anti-CD28-treated	I-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
restores	O
production	O
of	O
IL-5	O
,	O
TNF-alpha	B-protein
,	O
and	O
IFN-gamma	B-protein
,	O
but	O
not	O
IL-3	B-protein
and	O
GM-CSF	B-protein
expression	O
to	O
approximately	O
normal	O
levels	O
.	O

In	O
contrast	O
to	O
mitogen-activated	B-cell_line
Rel-/-	I-cell_line
T	I-cell_line
cells	I-cell_line
,	O
lipopolysaccharide-stimulated	O
Rel-/-	B-cell_line
macrophages	I-cell_line
produce	O
higher	O
than	O
normal	O
levels	O
of	O
GM-CSF	B-protein
.	O

These	O
findings	O
establish	O
that	O
Rel	B-protein
can	O
function	O
as	O
an	O
activator	O
or	O
repressor	O
of	O
gene	O
expression	O
and	O
is	O
required	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
for	O
production	O
of	O
IL-3	B-protein
and	O
GM-CSF	B-protein
.	O

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
Vol	NULL
.	NULL

93	NULL
,	NULL
pp	NULL
.	NULL

3405-3409	NULL
,	NULL
April	NULL
1996	NULL
Immunology	NULL
Rel-deficient	NULL
T	NULL
cells	NULL
exhibit	NULL
defects	NULL
in	NULL
production	NULL
of	NULL
interleukin	NULL
3	NULL
and	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
transcription	NULL
factors	NULL
)	NULL
STEVE	NULL
GERONDAKIS*	NULL
,	NULL
ANDREAS	NULL
STRASSER	NULL
,	NULL
DONALD	NULL
METCALF	NULL
,	NULL
GEORGE	NULL
GRIGORIADIS	NULL
,	NULL
JEAN-PIERRE	NULL
Y.	NULL
SCHEERLINCK	NULL
,	NULL
AND	NULL
RAELENE	NULL
J.	NULL
GRUMONT	NULL
The	NULL
Walter	NULL
and	NULL
Eliza	NULL
Hall	NULL
Institute	NULL
of	NULL
Medical	NULL
Research	NULL
,	NULL
P.O	NULL
.	NULL

Box	NULL
,	NULL
The	NULL
Royal	NULL
Melbourne	NULL
Hospital	NULL
,	NULL
Parkville	NULL
,	NULL
Victoria	NULL
3050	NULL
,	NULL
Australia	NULL
Communicated	NULL
by	NULL
G.	NULL
J.	NULL
V.	NULL
Nossal	NULL
,	NULL
The	NULL
Walter	NULL
and	NULL
Eliza	NULL
Hall	NULL
Institute	NULL
of	NULL
Medical	NULL
Research	NULL
,	NULL
Victoria	NULL
,	NULL
Australia	NULL
,	NULL
December	NULL
27	NULL
,	NULL
1995	NULL
(	NULL
received	NULL
for	NULL
review	NULL
November	NULL
2	NULL
,	NULL
1995	NULL
)	NULL
ABSTRACT	NULL
The	NULL
c-rel	NULL
protooncogene	NULL
encodes	NULL
a	NULL
subunit	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-like	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Mice	NULL
lacking	NULL
Rel	NULL
are	NULL
defective	NULL
in	NULL
mitogenic	NULL
activation	NULL
of	NULL
B	NULL
and	NULL
T	NULL
lymphocytes	NULL
and	NULL
display	NULL
impaired	NULL
humoral	NULL
immunity	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
identify	NULL
changes	NULL
in	NULL
gene	NULL
expression	NULL
that	NULL
accompany	NULL
the	NULL
T-cell	NULL
stimulation	NULL
defects	NULL
associated	NULL
with	NULL
the	NULL
loss	NULL
of	NULL
Rel	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
the	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
activation	NULL
markers	NULL
and	NULL
cytokine	NULL
production	NULL
in	NULL
mitogen-stimulated	NULL
Rel~'-	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
cell	NULL
surface	NULL
markers	NULL
including	NULL
the	NULL
interleukin	NULL
2	NULL
receptor	NULL
&	NULL
(	NULL
IL-2Ra	NULL
)	NULL
chain	NULL
(	NULL
CD25	NULL
)	NULL
,	NULL
CD69	NULL
and	NULL
L-selectin	NULL
(	NULL
CD62	NULL
)	NULL
is	NULL
normal	NULL
in	NULL
mitogen-activated	NULL
Rel~/-	NULL
T	NULL
cells	NULL
,	NULL
but	NULL
cytokine	NULL
production	NULL
is	NULL
impaired	NULL
.	NULL

In	NULL
Rel~/~	NULL
splenic	NULL
T	NULL
cell	NULL
cultures	NULL
stimulated	NULL
with	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
and	NULL
ionomycin	NULL
,	NULL
the	NULL
levels	NULL
of	NULL
IL-3	NULL
,	NULL
IL-5	NULL
,	NULL
granulocyte	NULL
macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
(	NULL
TNF-a	NULL
)	NULL
,	NULL
and	NULL
y	NULL
interferon	NULL
(	NULL
IFN-y	NULL
)	NULL
were	NULL
only	NULL
2-	NULL
to	NULL
3-fold	NULL
lower	NULL
compared	NULL
with	NULL
normal	NULL
T	NULL
cells	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
stimulated	NULL
Rel~~-	NULL
T	NULL
cells	NULL
,	NULL
which	NULL
fail	NULL
to	NULL
proliferate	NULL
,	NULL
make	NULL
little	NULL
or	NULL
no	NULL
detectable	NULL
cytokines	NULL
.	NULL

Exogenous	NULL
IL-2	NULL
,	NULL
which	NULL
restitutes	NULL
the	NULL
proliferative	NULL
response	NULL
of	NULL
the	NULL
anti-CD3-	NULL
and	NULL
anti-CD28-treated	NULL
Rel~/~	NULL
T	NULL
cells	NULL
,	NULL
restores	NULL
production	NULL
of	NULL
IL-5	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
IFN-y	NULL
,	NULL
but	NULL
not	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
expression	NULL
to	NULL
approximately	NULL
normal	NULL
levels	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
mitogen-activated	NULL
Rel~	NULL
``	NULL
~-	NULL
T	NULL
cells	NULL
,	NULL
lipopolysaccharide-stimulated	NULL
Rel~	NULL
``	NULL
~	NULL
macrophages	NULL
produce	NULL
higher	NULL
than	NULL
normal	NULL
levels	NULL
of	NULL
GM-CSF	NULL
.	NULL

These	NULL
findings	NULL
establish	NULL
that	NULL
Rel	NULL
can	NULL
function	NULL
as	NULL
an	NULL
activator	NULL
or	NULL
repressor	NULL
of	NULL
gene	NULL
expression	NULL
and	NULL
is	NULL
required	NULL
by	NULL
T	NULL
lymphocytes	NULL
for	NULL
production	NULL
of	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
.	NULL

Rel/NF-	NULL
«	NULL
B	NULL
transcription	NULL
factors	NULL
are	NULL
homo-	NULL
and	NULL
heterodimeric	NULL
proteins	NULL
composed	NULL
of	NULL
subunits	NULL
encoded	NULL
by	NULL
a	NULL
small	NULL
multigene	NULL
family	NULL
related	NULL
to	NULL
the	NULL
c-re/	NULL
protooncogene	NULL
(	NULL
1	NULL
,	NULL
2	NULL
)	NULL
.	NULL

Rel/NF-	NULL
«	NULL
B	NULL
factors	NULL
regulate	NULL
transcription	NULL
by	NULL
binding	NULL
to	NULL
decameric	NULL
sequences	NULL
(	NULL
«	NULL
B	NULL
motifs	NULL
)	NULL
in	NULL
the	NULL
promoters	NULL
and	NULL
enhancers	NULL
of	NULL
many	NULL
viral	NULL
and	NULL
cellular	NULL
genes	NULL
,	NULL
in	NULL
particular	NULL
those	NULL
that	NULL
encode	NULL
proteins	NULL
involved	NULL
in	NULL
immune	NULL
,	NULL
acute	NULL
phase	NULL
and	NULL
inflammatory	NULL
responses	NULL
(	NULL
3-5	NULL
)	NULL
.	NULL

The	NULL
five	NULL
known	NULL
mammalian	NULL
Rel-related	NULL
pro-teins	NULL
,	NULL
NF-	NULL
«	NULL
B1	NULL
(	NULL
p50	NULL
,	NULL
p105	NULL
)	NULL
,	NULL
NF-	NULL
«	NULL
B2	NULL
(	NULL
p52	NULL
,	NULL
p100	NULL
)	NULL
,	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
,	NULL
RelB	NULL
,	NULL
and	NULL
Rel	NULL
share	NULL
a	NULL
conserved	NULL
300-amino	NULL
acid	NULL
N	NULL
terminus	NULL
[	NULL
Rel	NULL
homology	NULL
domain	NULL
(	NULL
RHD	NULL
)	NULL
]	NULL
that	NULL
encompasses	NULL
sequences	NULL
required	NULL
for	NULL
DNA	NULL
binding	NULL
,	NULL
protein	NULL
dimerization	NULL
,	NULL
and	NULL
nuclear	NULL
localization	NULL
(	NULL
1-5	NULL
)	NULL
.	NULL

The	NULL
C	NULL
termini	NULL
of	NULL
Rel-related	NULL
proteins	NULL
are	NULL
divergent	NULL
,	NULL
with	NULL
those	NULL
of	NULL
Rel	NULL
,	NULL
RelA	NULL
,	NULL
and	NULL
RelB	NULL
containing	NULL
transcriptional	NULL
transactivation	NULL
domains	NULL
(	NULL
1	NULL
,	NULL
4	NULL
)	NULL
.	NULL

In	NULL
most	NULL
cells	NULL
prior	NULL
to	NULL
stimulation	NULL
,	NULL
a	NULL
large	NULL
proportion	NULL
of	NULL
Rel/NF-	NULL
«	NULL
B	NULL
is	NULL
retained	NULL
in	NULL
the	NULL
cytoplasm	NULL
in	NULL
an	NULL
inactive	NULL
form	NULL
through	NULL
association	NULL
with	NULL
regulatory	NULL
IxB	NULL
proteins	NULL
(	NULL
1-5	NULL
)	NULL
.	NULL

A	NULL
wide	NULL
range	NULL
of	NULL
stimuli	NULL
promote	NULL
Rel/NF-	NULL
«	NULL
B	NULL
nuclear	NULL
localization	NULL
by	NULL
a	NULL
mecha-	NULL
The	NULL
publication	NULL
costs	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
page	NULL
charge	NULL
payment	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

§1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

3405	NULL
nism	NULL
that	NULL
involves	NULL
phosphorylation	NULL
and	NULL
subsequent	NULL
degradation	NULL
of	NULL
the	NULL
IxB	NULL
proteins	NULL
(	NULL
6	NULL
)	NULL
.	NULL

Expression	NULL
of	NULL
the	NULL
Rel	NULL
subunit	NULL
is	NULL
largely	NULL
confined	NULL
to	NULL
hemopoietic	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
.	NULL

In	NULL
the	NULL
B-lymphocyte	NULL
lineage	NULL
,	NULL
increased	NULL
Rel	NULL
expression	NULL
results	NULL
in	NULL
a	NULL
qualitative	NULL
change	NULL
in	NULL
the	NULL
subunit	NULL
composition	NULL
of	NULL
Rel/NF-	NULL
«	NULL
B	NULL
proteins	NULL
during	NULL
the	NULL
transition	NULL
from	NULL
a	NULL
pre-B	NULL
to	NULL
a	NULL
B	NULL
cell	NULL
(	NULL
9-11	NULL
)	NULL
.	NULL

A	NULL
rapid	NULL
increase	NULL
in	NULL
nuclear	NULL
levels	NULL
of	NULL
Rel	NULL
(	NULL
9	NULL
,	NULL
12	NULL
,	NULL
13	NULL
)	NULL
and	NULL
increased	NULL
c-ref	NULL
transcription	NULL
(	NULL
14	NULL
)	NULL
during	NULL
mitogenic	NULL
activation	NULL
of	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
implicates	NULL
Rel	NULL
in	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

Such	NULL
a	NULL
function	NULL
is	NULL
also	NULL
supported	NULL
indirectly	NULL
by	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
avian	NULL
viral	NULL
oncogene	NULL
v-re/	NULL
to	NULL
transform	NULL
both	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
(	NULL
15	NULL
)	NULL
.	NULL

While	NULL
genes	NULL
regulated	NULL
by	NULL
Rel/NF-	NULL
«	NULL
B	NULL
that	NULL
are	NULL
critical	NULL
for	NULL
B-cell	NULL
proliferation	NULL
are	NULL
yet	NULL
to	NULL
be	NULL
identified	NULL
,	NULL
Rel	NULL
is	NULL
implicated	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
number	NULL
of	NULL
genes	NULL
that	NULL
are	NULL
thought	NULL
to	NULL
be	NULL
crucial	NULL
for	NULL
T-cell	NULL
activation	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Rel	NULL
up-regulates	NULL
the	NULL
transcription	NULL
of	NULL
human	NULL
interleukin	NULL
2	NULL
receptor	NULL
a	NULL
(	NULL
IL-2Ra	NULL
)	NULL
chain	NULL
promoter	NULL
reporters	NULL
(	NULL
16	NULL
)	NULL
and	NULL
Rel/	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
involved	NULL
in	NULL
IL-2	NULL
transcription	NULL
(	NULL
12	NULL
,	NULL
17-19	NULL
)	NULL
.	NULL

Rel/	NULL
NF-	NULL
«	NULL
B	NULL
has	NULL
also	NULL
been	NULL
implicated	NULL
in	NULL
transcriptional	NULL
regulation	NULL
of	NULL
other	NULL
cytokine	NULL
genes	NULL
expressed	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
5	NULL
,	NULL
18	NULL
)	NULL
.	NULL

The	NULL
promoters	NULL
of	NULL
the	NULL
genes	NULL
encoding	NULL
IL-3	NULL
,	NULL
IL-5	NULL
,	NULL
IL-6	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
(	NULL
TNF-a	NULL
)	NULL
,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
(	NULL
GM-CSF	NULL
)	NULL
and	NULL
y	NULL
interferon	NULL
(	NULL
IFN-y	NULL
)	NULL
contain	NULL
«	NULL
B	NULL
sites	NULL
or	NULL
the	NULL
«	NULL
B-related	NULL
CK1/CD28	NULL
response	NULL
element	NULL
(	NULL
CD28RE	NULL
;	NULL
refs	NULL
.	NULL

20	NULL
and	NULL
21	NULL
)	NULL
.	NULL

The	NULL
CD28RE	NULL
,	NULL
which	NULL
is	NULL
involved	NULL
in	NULL
IL-2	NULL
(	NULL
20	NULL
)	NULL
and	NULL
GM-CSF	NULL
(	NULL
22	NULL
)	NULL
transcription	NULL
,	NULL
has	NULL
recently	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
Rel/NF-	NULL
«	NULL
B	NULL
complexes	NULL
(	NULL
21	NULL
)	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
the	NULL
physiological	NULL
role	NULL
of	NULL
Rel	NULL
,	NULL
we	NULL
have	NULL
used	NULL
gene	NULL
targeting	NULL
to	NULL
generate	NULL
mutant	NULL
mice	NULL
with	NULL
an	NULL
inacti-vated	NULL
c-re/	NULL
gene	NULL
(	NULL
19	NULL
)	NULL
.	NULL

In	NULL
these	NULL
mice	NULL
,	NULL
the	NULL
development	NULL
of	NULL
cells	NULL
from	NULL
all	NULL
hemopoeitic	NULL
lineages	NULL
appears	NULL
to	NULL
be	NULL
normal	NULL
,	NULL
but	NULL
humoral	NULL
immunity	NULL
is	NULL
impaired	NULL
.	NULL

Mature	NULL
B	NULL
and	NULL
T	NULL
cells	NULL
are	NULL
largely	NULL
unresponsive	NULL
to	NULL
a	NULL
number	NULL
of	NULL
mitogenic	NULL
stimuli	NULL
and	NULL
IL-2	NULL
expression	NULL
is	NULL
reduced	NULL
in	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
identify	NULL
further	NULL
changes	NULL
in	NULL
T-cell	NULL
gene	NULL
expression	NULL
associated	NULL
with	NULL
the	NULL
loss	NULL
of	NULL
Rel	NULL
,	NULL
we	NULL
examined	NULL
mitogen-activated	NULL
Rel-'~-	NULL
T	NULL
cells	NULL
for	NULL
impaired	NULL
regulation	NULL
of	NULL
cell	NULL
surface	NULL
activation	NULL
markers	NULL
and	NULL
cytokines	NULL
.	NULL

No	NULL
differences	NULL
were	NULL
detected	NULL
in	NULL
expression	NULL
of	NULL
a	NULL
range	NULL
of	NULL
cell	NULL
surface	NULL
markers	NULL
.	NULL

However	NULL
,	NULL
production	NULL
of	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
,	NULL
but	NULL
not	NULL
IL-5	NULL
,	NULL
TNF-a	NULL
,	NULL
or	NULL
IFN-y	NULL
,	NULL
was	NULL
diminished	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
T	NULL
cells	NULL
,	NULL
GM-CSF	NULL
production	NULL
by	NULL
lipolysaccharide-stimulated	NULL
Rel~	NULL
``	NULL
-	NULL
resident	NULL
peritoneal	NULL
macrophages	NULL
was	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
normal	NULL
cells	NULL
.	NULL

These	NULL
findings	NULL
directly	NULL
implicate	NULL
Rel	NULL
in	NULL
controlling	NULL
expression	NULL
of	NULL
a	NULL
subset	NULL
of	NULL
cytokine	NULL
genes	NULL
and	NULL
indicate	NULL
that	NULL
Rel	NULL
is	NULL
important	NULL
for	NULL
positive	NULL
and	NULL
negative	NULL
regulation	NULL
of	NULL
GM-CSF	NULL
expression	NULL
in	NULL
different	NULL
cell	NULL
types	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Lymphocyte	NULL
and	NULL
Macrophage	NULL
Activation	NULL
in	NULL
Tissue	NULL
Culture	NULL
.	NULL

Splenic	NULL
T	NULL
cells	NULL
of	NULL
~90	NULL
%	NULL
purity	NULL
isolated	NULL
as	NULL
described	NULL
(	NULL
19	NULL
)	NULL
from	NULL
Abbreviations	NULL
:	NULL
IL	NULL
,	NULL
interleukin	NULL
;	NULL
TNF-a	NULL
«	NULL
,	NULL
tumor	NULL
necrosis	NULL
factor	NULL
a	NULL
;	NULL
GM-CSF	NULL
,	NULL
granulocyte-macrophage	NULL
colony-stimulating	NULL
factor	NULL
;	NULL
IFN-y	NULL
,	NULL
interferon	NULL
y	NULL
,	NULL
CD28RE	NULL
,	NULL
CD28	NULL
response	NULL
element	NULL
;	NULL
PMA	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
.	NULL

*To	NULL
whom	NULL
reprint	NULL
requests	NULL
should	NULL
be	NULL
addressed	NULL
.	NULL

3406	NULL
Immunology	NULL
:	NULL
Gerondakis	NULL
et	NULL
al	NULL
.	NULL

4-	NULL
to	NULL
6-week-old	NULL
normal	NULL
and	NULL
Rel-deficient	NULL
mice	NULL
were	NULL
stimulated	NULL
for	NULL
up	NULL
to	NULL
72	NULL
hr	NULL
in	NULL
RPMI	NULL
1640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
and	NULL
50	NULL
uM	NULL
2-mercaptoethanol	NULL
at	NULL
a	NULL
concentration	NULL
of	NULL
5	NULL
%	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
mouse	NULL
recombinant	NULL
IL-2	NULL
(	NULL
200	NULL
units/ml	NULL
;	NULL
Cetus	NULL
)	NULL
with	NULL
concanavalin	NULL
A	NULL
(	NULL
Pharmacia	NULL
)	NULL
at	NULL
2	NULL
ug/ml	NULL
,	NULL
phorbol	NULL
12-myristate	NULL
13-acetate	NULL
(	NULL
PMA	NULL
;	NULL
Sigma	NULL
)	NULL
plus	NULL
ionomycin	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
2	NULL
ng/ml	NULL
and	NULL
1	NULL
ug/ml	NULL
,	NULL
respectively	NULL
,	NULL
or	NULL
on	NULL
tissue	NULL
culture	NULL
plates	NULL
coated	NULL
with	NULL
monoclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
mouse	NULL
CD3	NULL
(	NULL
clone	NULL
145-2C11	NULL
;	NULL
ref	NULL
.	NULL

23	NULL
)	NULL
and	NULL
mouse	NULL
CD28	NULL
(	NULL
clone	NULL
37.51	NULL
;	NULL
ref	NULL
.	NULL

24	NULL
)	NULL
at	NULL
antibody	NULL
concentrations	NULL
of	NULL
10	NULL
mg/m	NULL
!	NULL

in	NULL
the	NULL
coating	NULL
solution	NULL
.	NULL

Resident	NULL
peritoneal	NULL
macrophages	NULL
isolated	NULL
from	NULL
6-	NULL
to	NULL
8-week-old	NULL
mice	NULL
were	NULL
first	NULL
purified	NULL
by	NULL
adherence	NULL
to	NULL
plastic	NULL
dishes	NULL
for	NULL
3	NULL
hr	NULL
and	NULL
then	NULL
cultured	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cells	NULL
per	NULL
ml	NULL
in	NULL
Dulbecco	NULL
's	NULL
Modified	NULL
Eagles	NULL
medium	NULL
containing	NULL
10	NULL
%	NULL
fetal	NULL
calf	NULL
serum	NULL
and	NULL
lipopolysaccharide	NULL
at	NULL
0.1	NULL
or	NULL
1	NULL
ug/ml	NULL
for	NULL
24-48	NULL
hr	NULL
.	NULL

Immunofluorescence	NULL
Staining	NULL
and	NULL
Flow	NULL
Cytometry	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
IL-2Ra	NULL
chain	NULL
(	NULL
CD25	NULL
)	NULL
,	NULL
CD69	NULL
,	NULL
and	NULL
L-selectin	NULL
(	NULL
CD62	NULL
)	NULL
were	NULL
analyzed	NULL
on	NULL
T	NULL
cells	NULL
before	NULL
and	NULL
after	NULL
24	NULL
,	NULL
48	NULL
,	NULL
and	NULL
72	NULL
hr	NULL
of	NULL
stimulation	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
as	NULL
described	NULL
(	NULL
25	NULL
)	NULL
with	NULL
anti-Thy1.2-FITC	NULL
(	NULL
clone	NULL
30H12	NULL
;	NULL
Becton	NULL
Dickinson	NULL
)	NULL
and	NULL
with	NULL
biotinylated	NULL
monoclonal	NULL
antibodies	NULL
specific	NULL
for	NULL
IL-2Ra	NULL
chain	NULL
(	NULL
clone	NULL
PC61	NULL
)	NULL
,	NULL
CD69	NULL
(	NULL
clone	NULL
H1.2F3	NULL
)	NULL
,	NULL
or	NULL
CD62/L-selectin	NULL
(	NULL
clone	NULL
Mel-14	NULL
)	NULL
or	NULL
with	NULL
a	NULL
biotinylated	NULL
isotype-matched	NULL
control	NULL
monoclonal	NULL
antibody	NULL
.	NULL

Binding	NULL
of	NULL
biotinylated	NULL
antibodies	NULL
was	NULL
revealed	NULL
by	NULL
staining	NULL
with	NULL
phycoerythrin/streptavidin	NULL
(	NULL
Caltag	NULL
)	NULL
as	NULL
the	NULL
secondary	NULL
reagent	NULL
.	NULL

Cytokine	NULL
Assays	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
IL-3	NULL
,	NULL
IL-5	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
GM-CSF	NULL
in	NULL
T-cell	NULL
culture	NULL
supernatants	NULL
were	NULL
determined	NULL
by	NULL
ELISA	NULL
(	NULL
Pharmingen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
CA	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

IL-3	NULL
levels	NULL
were	NULL
also	NULL
determined	NULL
by	NULL
bioassay	NULL
using	NULL
IL-3-responsive	NULL
32D	NULL
cells	NULL
(	NULL
26	NULL
)	NULL
,	NULL
and	NULL
the	NULL
level	NULL
of	NULL
IFN-y	NULL
was	NULL
``	NULL
detected	NULL
by	NULL
using	NULL
the	NULL
IFN-y	NULL
sensitive	NULL
cell	NULL
line	NULL
WEHI279	NULL
as	NULL
described	NULL
(	NULL
27	NULL
)	NULL
.	NULL

GM-CSF	NULL
levels	NULL
produced	NULL
by	NULL
stimulated	NULL
peritoneal	NULL
macrophages	NULL
were	NULL
determined	NULL
by	NULL
bioassay	NULL
as	NULL
described	NULL
(	NULL
28	NULL
)	NULL
.	NULL

All	NULL
cytokine	NULL
assays	NULL
were	NULL
standardized	NULL
by	NULL
including	NULL
a	NULL
titration	NULL
of	NULL
the	NULL
appropriate	NULL
purified	NULL
recombinant	NULL
cytokine	NULL
of	NULL
known	NULL
activity	NULL
.	NULL

RESULTS	NULL
The	NULL
Expression	NULL
Pattern	NULL
of	NULL
T	NULL
Cell	NULL
Surface	NULL
Markers	NULL
Is	NULL
Normal	NULL
in	NULL
Mitogen-Activated	NULL
Rel-Deficient	NULL
Cells	NULL
.	NULL

Although	NULL
expression	NULL
of	NULL
a	NULL
wide	NULL
range	NULL
of	NULL
cell	NULL
surface	NULL
markers	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
normal	NULL
in	NULL
naive	NULL
Rel-deficient	NULL
T	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
,	NULL
a	NULL
lack	NULL
of	NULL
response	NULL
to	NULL
certain	NULL
modes	NULL
of	NULL
activation	NULL
prompted	NULL
a	NULL
study	NULL
of	NULL
surface	NULL
marker	NULL
expression	NULL
during	NULL
mitogenic	NULL
stimulation	NULL
.	NULL

Changes	NULL
in	NULL
expression	NULL
of	NULL
a	NULL
number	NULL
of	NULL
surface	NULL
markers	NULL
normally	NULL
occurs	NULL
with	NULL
the	NULL
onset	NULL
of	NULL
T-cell	NULL
activation	NULL
.	NULL

CD69	NULL
(	NULL
29	NULL
)	NULL
,	NULL
CD25/IL-2Ra	NULL
chain	NULL
(	NULL
30	NULL
)	NULL
,	NULL
CD44/Pgpl	NULL
(	NULL
30	NULL
)	NULL
,	NULL
and	NULL
the	NULL
Fas/	NULL
Apo-1	NULL
(	NULL
CD95	NULL
)	NULL
receptor	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
are	NULL
all	NULL
up-regulated	NULL
during	NULL
T-cell	NULL
stimulation	NULL
,	NULL
while	NULL
L-selectin/CD62	NULL
(	NULL
33	NULL
)	NULL
and	NULL
the	NULL
CD45	NULL
isoform	NULL
CD45RB	NULL
(	NULL
33	NULL
)	NULL
are	NULL
down-regulated	NULL
.	NULL

Flow	NULL
cytometry	NULL
was	NULL
used	NULL
to	NULL
monitor	NULL
expression	NULL
of	NULL
these	NULL
cell	NULL
surface	NULL
markers	NULL
in	NULL
normal	NULL
and	NULL
in	NULL
Rel~'~	NULL
T	NULL
cells	NULL
stimulated	NULL
over	NULL
a	NULL
72-hr	NULL
time	NULL
course	NULL
with	NULL
PMA	NULL
and	NULL
ionomycin	NULL
or	NULL
with	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
.	NULL

A	NULL
representative	NULL
sample	NULL
of	NULL
results	NULL
from	NULL
these	NULL
experiments	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
clearly	NULL
establishes	NULL
that	NULL
72	NULL
hr	NULL
poststimulation	NULL
the	NULL
expression	NULL
of	NULL
CD25	NULL
,	NULL
CD69	NULL
,	NULL
and	NULL
MEL14	NULL
in	NULL
response	NULL
to	NULL
both	NULL
sets	NULL
of	NULL
stimuli	NULL
is	NULL
normal	NULL
.	NULL

An	NULL
examination	NULL
of	NULL
these	NULL
and	NULL
other	NULL
cell	NULL
surface	NULL
markers	NULL
after	NULL
24	NULL
and	NULL
48	NULL
hr	NULL
of	NULL
stimulation	NULL
confirmed	NULL
that	NULL
the	NULL
kinetics	NULL
of	NULL
expression	NULL
on	NULL
Rel~/~	NULL
T	NULL
cells	NULL
was	NULL
also	NULL
normal	NULL
(	NULL
results	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
therefore	NULL
document	NULL
that	NULL
Rel	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
expression	NULL
of	NULL
these	NULL
proteins	NULL
.	NULL

The	NULL
Expression	NULL
of	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
Is	NULL
Reduced	NULL
in	NULL
Mitogen-Stimulated	NULL
Rel-Deficient	NULL
T	NULL
Cells	NULL
.	NULL

Activated	NULL
T	NULL
cells	NULL
secrete	NULL
a	NULL
number	NULL
of	NULL
cytokines	NULL
that	NULL
are	NULL
critical	NULL
in	NULL
modulation	NULL
of	NULL
immune	NULL
responses	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
Rel~	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
make	NULL
reduced	NULL
levels	NULL
of	NULL
IL-2	NULL
(	NULL
19	NULL
)	NULL
prompted	NULL
us	NULL
to	NULL
compare	NULL
the	NULL
cytokine	NULL
secretion	NULL
profile	NULL
of	NULL
normal	NULL
and	NULL
Rel~/~	NULL
T	NULL
cells	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
stimulated	NULL
with	NULL
different	NULL
mitogenic	NULL
agents	NULL
for	NULL
72	NULL
hr	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
.	NULL

Cytokine	NULL
levels	NULL
were	NULL
consistently	NULL
lower	NULL
in	NULL
stimulated	NULL
Rel~'~	NULL
T	NULL
cell	NULL
cultures	NULL
,	NULL
with	NULL
the	NULL
relative	NULL
difference	NULL
in	NULL
expression	NULL
of	NULL
each	NULL
cytokine	NULL
dependent	NULL
on	NULL
the	NULL
stimulus	NULL
.	NULL

For	NULL
example	NULL
,	NULL
while	NULL
cytokine	NULL
levels	NULL
in	NULL
PMA	NULL
plus	NULL
ionomycin-stimulated	NULL
Rel~/-	NULL
T	NULL
cells	NULL
were	NULL
equivalent	NULL
to	NULL
or	NULL
only	NULL
severalfold	NULL
lower	NULL
than	NULL
in	NULL
normal	NULL
cultures	NULL
,	NULL
cytokine	NULL
levels	NULL
in	NULL
anti-CD3	NULL
plus	NULL
anti-CD2§-stimulated	NULL
Rel~	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
were	NULL
reduced	NULL
12-	NULL
and	NULL
~80-fold	NULL
for	NULL
GM-CSF	NULL
and	NULL
IL-3	NULL
,	NULL
respectively	NULL
.	NULL

The	NULL
poor	NULL
proliferative	NULL
response	NULL
of	NULL
anti-CD3	NULL
plus	NULL
anti-CD28-stimulated	NULL
Rel-	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
compared	NULL
with	NULL
that	NULL
elicited	NULL
by	NULL
PMA	NULL
and	NULL
ionomycin	NULL
(	NULL
19	NULL
)	NULL
prompted	NULL
an	NULL
examination	NULL
of	NULL
cytokine	NULL
production	NULL
by	NULL
mitogen-stimulated	NULL
cultures	NULL
supplemented	NULL
with	NULL
IL-2	NULL
.	NULL

Addition	NULL
of	NULL
IL-2	NULL
,	NULL
which	NULL
restores	NULL
Rel~'~	NULL
T	NULL
cell	NULL
proliferative	NULL
responses	NULL
to	NULL
that	NULL
of	NULL
normal	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
,	NULL
should	NULL
distinguish	NULL
between	NULL
reduced	NULL
cytokine	NULL
production	NULL
due	NULL
directly	NULL
to	NULL
the	NULL
loss	NULL
of	NULL
Rel	NULL
or	NULL
as	NULL
a	NULL
secondary	NULL
effect	NULL
resulting	NULL
from	NULL
the	NULL
lack	NULL
of	NULL
proliferation	NULL
.	NULL

These	NULL
experiments	NULL
(	NULL
Table	NULL
1	NULL
)	NULL
establish	NULL
that	NULL
defects	NULL
in	NULL
cytokine	NULL
production	NULL
by	NULL
Rel~	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
fall	NULL
into	NULL
two	NULL
groups	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
IFN-y	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
IL-5	NULL
now	NULL
produced	NULL
by	NULL
stimulated	NULL
Rel~	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
was	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
normal	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
reduced	NULL
levels	NULL
of	NULL
these	NULL
cytokines	NULL
appear	NULL
to	NULL
be	NULL
due	NULL
to	NULL
the	NULL
impaired	NULL
proliferative	NULL
response	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
the	NULL
amount	NULL
of	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
produced	NULL
by	NULL
anti-CD3	NULL
plus	NULL
anti-CD28-stimulated	NULL
Rel~/~	NULL
cells	NULL
supplemented	NULL
with	NULL
IL-2	NULL
was	NULL
still	NULL
16-	NULL
and	NULL
11-fold	NULL
lower	NULL
,	NULL
respectively	NULL
,	NULL
than	NULL
that	NULL
made	NULL
by	NULL
normal	NULL
T	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
Rel	NULL
was	NULL
essential	NULL
for	NULL
normal	NULL
expression	NULL
of	NULL
these	NULL
cytokines	NULL
.	NULL

Rel	NULL
Has	NULL
Opposite	NULL
Effects	NULL
on	NULL
Regulation	NULL
of	NULL
GM-CSF	NULL
Expression	NULL
in	NULL
T	NULL
Cells	NULL
and	NULL
Macrophages	NULL
.	NULL

GM-CSF	NULL
can	NULL
be	NULL
produced	NULL
not	NULL
only	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
but	NULL
also	NULL
by	NULL
a	NULL
number	NULL
of	NULL
cell	NULL
types	NULL
including	NULL
fibroblasts	NULL
,	NULL
macrophages	NULL
,	NULL
and	NULL
endothelial	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
by	NULL
cytokines	NULL
,	NULL
antigens	NULL
,	NULL
or	NULL
inflammatory	NULL
agents	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Since	NULL
Rel	NULL
expression	NULL
is	NULL
largely	NULL
confined	NULL
to	NULL
hemopoietic	NULL
cells	NULL
(	NULL
7	NULL
,	NULL
8	NULL
)	NULL
,	NULL
GM-CSF	NULL
production	NULL
was	NULL
also	NULL
examined	NULL
in	NULL
macrophages	NULL
from	NULL
Rel~	NULL
``	NULL
~	NULL
mice	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
reduced	NULL
GM-CSF	NULL
levels	NULL
secreted	NULL
by	NULL
mitogen-stimulated	NULL
Rel~	NULL
'	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
,	NULL
resident	NULL
Rel~'~	NULL
peritoneal	NULL
macrophages	NULL
treated	NULL
with	NULL
lipopolysaccharide	NULL
for	NULL
24	NULL
or	NULL
48	NULL
hr	NULL
produce	NULL
10-	NULL
to	NULL
50-fold	NULL
more	NULL
GM-CSF	NULL
than	NULL
normal	NULL
macrophages	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

This	NULL
did	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
a	NULL
lipopolysaccharide	NULL
concentration-dependent	NULL
phenomenon	NULL
,	NULL
since	NULL
0.1	NULL
or	NULL
1	NULL
ug/ml	NULL
of	NULL
lipopolysaccharide	NULL
per	NULL
ml	NULL
both	NULL
resulted	NULL
in	NULL
elevated	NULL
production	NULL
of	NULL
GM-CSF	NULL
from	NULL
Rel~'~	NULL
macrophages	NULL
.	NULL

The	NULL
basis	NULL
for	NULL
the	NULL
slight	NULL
reduction	NULL
in	NULL
GM-CSF	NULL
levels	NULL
produced	NULL
by	NULL
both	NULL
the	NULL
normal	NULL
and	NULL
Rel~	NULL
``	NULL
~	NULL
cultures	NULL
after	NULL
48	NULL
hr	NULL
stimulation	NULL
compared	NULL
with	NULL
that	NULL
seen	NULL
after	NULL
24	NULL
hr	NULL
most	NULL
likely	NULL
reflects	NULL
GM-CSF	NULL
consumption	NULL
by	NULL
the	NULL
macrophages	NULL
.	NULL

Consistent	NULL
with	NULL
the	NULL
levels	NULL
of	NULL
GM-CSF	NULL
determined	NULL
by	NULL
bioassay	NULL
and	NULL
ELISA	NULL
,	NULL
Northern	NULL
blot	NULL
analysis	NULL
confirmed	NULL
that	NULL
GM-CSF	NULL
mRNA	NULL
levels	NULL
were	NULL
reduced	NULL
in	NULL
Rel~	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
and	NULL
elevated	NULL
in	NULL
Rel~	NULL
``	NULL
~	NULL
macrophages	NULL
compared	NULL
with	NULL
their	NULL
normal	NULL
counterparts	NULL
(	NULL
S.G.	NULL
and	NULL
G.G	NULL
.	NULL

,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
results	NULL
establish	NULL
that	NULL
Rel	NULL
can	NULL
function	NULL
as	NULL
both	NULL
an	NULL
activator	NULL
and	NULL
repressor	NULL
of	NULL
induced	NULL
GM-CSF	NULL
expression	NULL
in	NULL
different	NULL
activated	NULL
cell	NULL
types	NULL
.	NULL

DISCUSSION	NULL
Changes	NULL
in	NULL
expression	NULL
of	NULL
many	NULL
genes	NULL
accompany	NULL
T-cell	NULL
activation	NULL
(	NULL
36	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
T	NULL
cells	NULL
from	NULL
Rel~	NULL
``	NULL
~	NULL
mice	NULL
exhibit	NULL
defects	NULL
in	NULL
proliferation	NULL
and	NULL
reduced	NULL
IL-2	NULL
expression	NULL
(	NULL
19	NULL
)	NULL
prompted	NULL
a	NULL
detailed	NULL
study	NULL
of	NULL
gene	NULL
expression	NULL
during	NULL
the	NULL
mitogenic	NULL
activation	NULL
of	NULL
Rel~	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
expression	NULL
pattern	NULL
of	NULL
cell	NULL
surface	NULL
markers	NULL
including	NULL
CD25	NULL
,	NULL
CD44	NULL
,	NULL
CD45RB	NULL
,	NULL
CD69	NULL
,	NULL
and	NULL
CD95	NULL
,	NULL
all	NULL
of	NULL
which	NULL
normally	NULL
change	NULL
during	NULL
T-cell	NULL
activation	NULL
(	NULL
29-33	NULL
)	NULL
,	NULL
were	NULL
unaffected	NULL
in	NULL
Rel~/~-	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
observation	NULL
that	NULL
Rel	NULL
is	NULL
not	NULL
essential	NULL
for	NULL
basal	NULL
or	NULL
induced	NULL
IL-2Ra	NULL
chain	NULL
gene	NULL
expression	NULL
in	NULL
murine	NULL
T	NULL
cells	NULL
was	NULL
surprising	NULL
.	NULL

Although	NULL
Rel	NULL
binds	NULL
to	NULL
a	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
the	NULL
human	NULL
IL-2Ra	NULL
chain	NULL
gene	NULL
required	NULL
for	NULL
Rel-dependent	NULL
transactivation	NULL
Immunology	NULL
:	NULL
Gerondakis	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
3407	NULL
control	NULL
(	NULL
day	NULL
0	NULL
)	NULL
C	NULL
R	NULL
CD69	NULL
|	NULL
CD25	NULL
|	NULL
CD62	NULL
|	NULL
|	NULL
wt	NULL
109	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
109°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
10°	NULL
101	NULL
102	NULL
103	NULL
104	NULL
|	NULL
C	NULL
CDég	NULL
CD25	NULL
|	NULL
Cos2	NULL
|	NULL
Rel	NULL
-/-al	NULL
a	NULL
al	NULL
mal	NULL
aad	NULL
|	NULL
haa	NULL
aul	NULL
109	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
109	NULL
101	NULL
102	NULL
103	NULL
104	NULL
109°	NULL
10	NULL
%	NULL
102	NULL
103	NULL
104	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
anti-CD3	NULL
+	NULL
anti-CD28	NULL
(	NULL
day	NULL
3	NULL
)	NULL
L	NULL
C	NULL
L	NULL
CD69	NULL
R	NULL
CD25	NULL
ﬂ	NULL
und	NULL
iad	NULL
a.	NULL
ual	NULL
a	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
10°	NULL
101	NULL
102	NULL
103	NULL
104	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
|	NULL
C	NULL
|	NULL
CD69	NULL
|	NULL
CD25	NULL
CD62	NULL
|	NULL
|	NULL
L	NULL
Rel	NULL
-/-wl	NULL
ud	NULL
ud	NULL
.	NULL

nd	NULL
ad	NULL
ad	NULL
vad	NULL
109°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
109°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
PMA	NULL
+	NULL
ionomycin	NULL
(	NULL
day	NULL
3	NULL
)	NULL
L	NULL
C	NULL
L	NULL
CD69	NULL
|	NULL
CD25	NULL
L	NULL
CD62	NULL
|	NULL
|	NULL
|	NULL
|	NULL
wt	NULL
aat	NULL
aad	NULL
iin	NULL
al	NULL
iud	NULL
1s	NULL
WW	NULL
R	NULL
“	NULL
A	NULL
;	NULL
fad	NULL
.	NULL

i	NULL
ccuel	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
109	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
10°	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
R	NULL
C	NULL
|	NULL
CD69	NULL
|	NULL
CD25	NULL
CD62	NULL
-	NULL
-	NULL
-	NULL
-	NULL
Rel	NULL
-/-|-	NULL
-	NULL
.-pil	NULL
ud	NULL
ad	NULL
.	NULL

ual	NULL
Pu	NULL
a	NULL
icued	NULL
ad	NULL
lud	NULL
mal	NULL
100	NULL
101	NULL
102	NULL
103	NULL
104	NULL
109	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
109°	NULL
101	NULL
102	NULL
103	NULL
104	NULL
109	NULL
10	NULL
!	NULL

102	NULL
103	NULL
104	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Expression	NULL
of	NULL
cell	NULL
surface	NULL
activation	NULL
markers	NULL
on	NULL
T	NULL
cells	NULL
from	NULL
Rel~/~	NULL
mice	NULL
.	NULL

Spleen	NULL
cells	NULL
from	NULL
normal	NULL
and	NULL
Rel~	NULL
``	NULL
~	NULL
mice	NULL
were	NULL
stimulated	NULL
in	NULL
tissue	NULL
culture	NULL
either	NULL
with	NULL
immobilized	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
or	NULL
with	NULL
PMA	NULL
plus	NULL
ionomycin	NULL
.	NULL

Expression	NULL
of	NULL
IL-2Ra	NULL
«	NULL
chain	NULL
(	NULL
CD25	NULL
)	NULL
,	NULL
CD69	NULL
,	NULL
and	NULL
L-selectin	NULL
(	NULL
CD62	NULL
)	NULL
was	NULL
analyzed	NULL
on	NULL
T	NULL
cells	NULL
(	NULL
identified	NULL
as	NULL
being	NULL
Th1.2	NULL
positive	NULL
)	NULL
before	NULL
and	NULL
after	NULL
72	NULL
hr	NULL
of	NULL
stimulation	NULL
.	NULL

Data	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
and	NULL
are	NULL
presented	NULL
as	NULL
histograms	NULL
of	NULL
fluorescence	NULL
intensity	NULL
of	NULL
Thy1.2-positive	NULL
gated	NULL
T	NULL
cells	NULL
.	NULL

of	NULL
reporter	NULL
constructs	NULL
(	NULL
16	NULL
)	NULL
and	NULL
v-re/	NULL
upregulates	NULL
avian	NULL
IL-2Ra	NULL
chain	NULL
expression	NULL
in	NULL
Rev-T-transformed	NULL
lymphoid	NULL
cells	NULL
(	NULL
37	NULL
)	NULL
,	NULL
a	NULL
comparison	NULL
of	NULL
mouse	NULL
and	NULL
human	NULL
IL-2Ra	NULL
chain	NULL
gene	NULL
promoter	NULL
sequences	NULL
(	NULL
38	NULL
)	NULL
may	NULL
explain	NULL
the	NULL
basis	NULL
of	NULL
this	NULL
unexpected	NULL
species-specific	NULL
difference	NULL
.	NULL

The	NULL
«	NULL
B	NULL
site	NULL
in	NULL
the	NULL
human	NULL
IL-Z2Ra	NULL
chain	NULL
promoter	NULL
,	NULL
5-GGGAATCTCC-3	NULL
'	NULL
,	NULL
differs	NULL
from	NULL
the	NULL
sequence	NULL
in	NULL
the	NULL
mouse	NULL
gene	NULL
,	NULL
5	NULL
-GGAATCCCCC-3	NULL
'	NULL
,	NULL
the	NULL
latter	NULL
of	NULL
which	NULL
is	NULL
a	NULL
poor	NULL
consensus	NULL
binding	NULL
site	NULL
for	NULL
Rel/NF-	NULL
«	NULL
B	NULL
proteins	NULL
(	NULL
1	NULL
,	NULL
3	NULL
,	NULL
39	NULL
)	NULL
.	NULL

Collectively	NULL
,	NULL
these	NULL
findings	NULL
suggest	NULL
that	NULL
Rel	NULL
is	NULL
not	NULL
important	NULL
in	NULL
murine	NULL
IL-2Ra	NULL
chain	NULL
gene	NULL
expression	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
regulation	NULL
of	NULL
cell	NULL
surface	NULL
markers	NULL
,	NULL
cytokine	NULL
gene	NULL
expression	NULL
is	NULL
perturbed	NULL
in	NULL
Rel-	NULL
``	NULL
~	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
levels	NULL
of	NULL
IL-2	NULL
(	NULL
19	NULL
)	NULL
,	NULL
IL-3	NULL
,	NULL
IL-5	NULL
,	NULL
GM-CSF	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
IFN-y	NULL
were	NULL
low	NULL
or	NULL
undetectable	NULL
in	NULL
concanavalin	NULL
A	NULL
or	NULL
anti-CD3	NULL
plus	NULL
anti-CD28-stimulated	NULL
Rel~/~	NULL
T-cell	NULL
cultures	NULL
.	NULL

Rescuing	NULL
the	NULL
proliferation	NULL
of	NULL
Rel~/~	NULL
T	NULL
cells	NULL
by	NULL
adding	NULL
IL-2	NULL
revealed	NULL
that	NULL
IL-5	NULL
,	NULL
TNF-a	NULL
,	NULL
and	NULL
IFN-y	NULL
production	NULL
was	NULL
restored	NULL
to	NULL
normal	NULL
levels	NULL
,	NULL
but	NULL
expression	NULL
of	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
remained	NULL
much	NULL
lower	NULL
than	NULL
in	NULL
the	NULL
normal	NULL
T-cell	NULL
cultures	NULL
.	NULL

These	NULL
findings	NULL
indicate	NULL
that	NULL
in	NULL
this	NULL
system	NULL
expression	NULL
of	NULL
some	NULL
but	NULL
not	NULL
all	NULL
cytokine	NULL
genes	NULL
appear	NULL
to	NULL
be	NULL
directly	NULL
controlled	NULL
in	NULL
part	NULL
by	NULL
Rel	NULL
and	NULL
that	NULL
cytokine	NULL
production	NULL
rather	NULL
than	NULL
cell	NULL
surface	NULL
marker	NULL
expression	NULL
may	NULL
be	NULL
a	NULL
more	NULL
accurate	NULL
gauge	NULL
of	NULL
T-cell	NULL
activation	NULL
.	NULL

While	NULL
the	NULL
ability	NULL
of	NULL
exogenous	NULL
IL-2	NULL
to	NULL
restitute	NULL
normal	NULL
expression	NULL
of	NULL
3408	NULL
Immunology	NULL
:	NULL
Gerondakis	NULL
et	NULL
al	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
Table	NULL
1	NULL
.	NULL

Cytokine	NULL
production	NULL
by	NULL
Rel	NULL
~/~	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
different	NULL
mitogenic	NULL
stimuli	NULL
IFN-y	NULL
,	NULL
IL-3	NULL
.	NULL

pg/ml	NULL
IL-5	NULL
,	NULL
pg/ml	NULL
GM-CSF	NULL
,	NULL
pg/ml	NULL
TNF-a	NULL
,	NULL
pg/ml	NULL
ng/ml	NULL
Stimulus	NULL
+/+	NULL
-/-	NULL
+/+	NULL
-/-	NULL
+/+	NULL
-/-	NULL
+/+	NULL
-/-	NULL
+/+	NULL
-/-None	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
l1-	NULL
<	NULL
1	NULL
IL-2	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
30	NULL
<	NULL
l-	NULL
<	NULL
1	NULL
Concanavalin	NULL
A	NULL
600	NULL
+	NULL
70	NULL
<	NULL
30	NULL
110	NULL
+	NULL
30	NULL
<	NULL
30	NULL
625	NULL
+	NULL
80	NULL
120	NULL
+	NULL
30	NULL
315	NULL
+	NULL
50	NULL
175	NULL
+	NULL
40	NULL
20	NULL
_-	NULL
ND	NULL
Concanavalin	NULL
A	NULL
+	NULL
IL-2	NULL
1,350	NULL
+	NULL
110	NULL
65	NULL
+	NULL
20	NULL
190	NULL
+	NULL
40	NULL
160	NULL
+	NULL
40	NULL
1025	NULL
+	NULL
110	NULL
_	NULL
170	NULL
+	NULL
20	NULL
480	NULL
+	NULL
70	NULL
350	NULL
+	NULL
50	NULL
20	NULL
15	NULL
PMA	NULL
+	NULL
ionomycin	NULL
75,000	NULL
+	NULL
5500	NULL
23,500	NULL
+	NULL
2100	NULL
410	NULL
+	NULL
60	NULL
250	NULL
+	NULL
30	NULL
5600	NULL
+	NULL
240	NULL
2350	NULL
+	NULL
180	NULL
1670	NULL
+	NULL
180	NULL
_	NULL
910	NULL
+	NULL
110	NULL
_	NULL
80	NULL
80	NULL
PMA	NULL
+	NULL
ionomycin	NULL
+	NULL
IL-2	NULL
68,000	NULL
+	NULL
4000	NULL
29,000	NULL
+	NULL
1500	NULL
-	NULL
520	NULL
+	NULL
40	NULL
-	NULL
470	NULL
+	NULL
50	NULL
7150	NULL
+	NULL
570	NULL
2650	NULL
+	NULL
190	NULL
2240	NULL
+	NULL
270	NULL
1820	NULL
+	NULL
210	NULL
_	NULL
80	NULL
80	NULL
Anti-CD3	NULL
+	NULL
anti-CD28	NULL
34,500	NULL
+	NULL
2500	NULL
450	NULL
+	NULL
70	NULL
340	NULL
+	NULL
30	NULL
<	NULL
30	NULL
4800	NULL
+	NULL
230	NULL
_	NULL
350	NULL
*+	NULL
60	NULL
_	NULL
2750	NULL
+	NULL
230	NULL
-	NULL
130	NULL
+	NULL
40	NULL
_	NULL
160	NULL
_	NULL
20	NULL
Anti-CD3	NULL
+	NULL
anti-CD28	NULL
+	NULL
IL-2	NULL
42,000	NULL
+	NULL
3100	NULL
_	NULL
2,600	NULL
+	NULL
160	NULL
_	NULL
480	NULL
+	NULL
40	NULL
540	NULL
+	NULL
60	NULL
7100	NULL
+	NULL
480	NULL
_	NULL
650	NULL
+	NULL
80	NULL
_	NULL
3060	NULL
+	NULL
240	NULL
3160	NULL
+	NULL
190	NULL
160	NULL
>	NULL
300	NULL
Specific	NULL
cytokine	NULL
levels	NULL
produced	NULL
by	NULL
T	NULL
cells	NULL
stimulated	NULL
for	NULL
72	NULL
hr	NULL
were	NULL
determined	NULL
by	NULL
comparing	NULL
supernatant	NULL
activities	NULL
with	NULL
those	NULL
of	NULL
purified	NULL
recombinant	NULL
cytokine	NULL
standards	NULL
and	NULL
were	NULL
converted	NULL
to	NULL
pg/ml	NULL
or	NULL
ng/ml	NULL
.	NULL

Means	NULL
*	NULL
SD	NULL
for	NULL
IL-3	NULL
,	NULL
IL-5	NULL
,	NULL
GM-CSF	NULL
,	NULL
and	NULL
TNF-a	NULL
were	NULL
determined	NULL
from	NULL
four	NULL
to	NULL
six	NULL
separate	NULL
experiments	NULL
.	NULL

IFN-y	NULL
levels	NULL
are	NULL
means	NULL
of	NULL
two	NULL
experiments	NULL
.	NULL

<	NULL
,	NULL
Cytokine	NULL
activities	NULL
lower	NULL
than	NULL
the	NULL
limit	NULL
of	NULL
sensitivity	NULL
for	NULL
detection	NULL
by	NULL
cither	NULL
cytokine	NULL
ELISA	NULL
or	NULL
bioassay	NULL
;	NULL
ND	NULL
,	NULL
not	NULL
determined	NULL
.	NULL

certain	NULL
T-cell	NULL
cytokines	NULL
is	NULL
consistent	NULL
with	NULL
cytokine	NULL
production	NULL
being	NULL
intimately	NULL
linked	NULL
to	NULL
proliferation	NULL
,	NULL
it	NULL
remains	NULL
a	NULL
formal	NULL
possibility	NULL
that	NULL
the	NULL
IL-2-mediated	NULL
rescue	NULL
of	NULL
IL-5	NULL
,	NULL
IFN-y	NULL
,	NULL
and	NULL
TNF-a	NULL
expression	NULL
in	NULL
anti-CD3	NULL
plus	NULL
anti-CD28-treated	NULL
Rel-deficient	NULL
T	NULL
cells	NULL
is	NULL
associated	NULL
with	NULL
an	NULL
aspect	NULL
of	NULL
T-cell	NULL
activation	NULL
that	NULL
is	NULL
independent	NULL
of	NULL
the	NULL
IL-2-dependent	NULL
proliferative	NULL
response	NULL
.	NULL

The	NULL
transcriptional	NULL
control	NULL
regions	NULL
of	NULL
the	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
GM-CSF	NULL
genes	NULL
share	NULL
a	NULL
number	NULL
of	NULL
regulatory	NULL
sequences	NULL
including	NULL
the	NULL
CK1	NULL
or	NULL
CD28RE	NULL
,	NULL
which	NULL
is	NULL
distinct	NULL
from	NULL
but	NULL
related	NULL
to	NULL
the	NULL
«	NULL
B	NULL
motif	NULL
and	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
bind	NULL
complexes	NULL
containing	NULL
NF-	NULL
«	NULL
BI1	NULL
,	NULL
RelA	NULL
,	NULL
and	NULL
Rel	NULL
(	NULL
21	NULL
)	NULL
.	NULL

A	NULL
compilation	NULL
of	NULL
CD28REs	NULL
within	NULL
cytokine	NULL
gene	NULL
promoters	NULL
is	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

The	NULL
GM-CSF	NULL
motif	NULL
is	NULL
a	NULL
perfect	NULL
match	NULL
with	NULL
the	NULL
Rel	NULL
homodimer	NULL
consensus	NULL
binding	NULL
site	NULL
5	NULL
!	NULL

-NGGNNA/TTTCC-3	NULL
'	NULL
(	NULL
39	NULL
)	NULL
,	NULL
while	NULL
the	NULL
sequences	NULL
from	NULL
the	NULL
IL-2	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
G-CSF	NULL
genes	NULL
differ	NULL
by	NULL
only	NULL
a	NULL
single	NULL
nucleotide	NULL
from	NULL
the	NULL
consensus	NULL
motif	NULL
.	NULL

Although	NULL
STIMULUS	NULL
_	NULL
NONE	NULL
LPS	NULL
NONE	NULL
LPS	NULL
0.1	NULL
ug	NULL
1	NULL
ug	NULL
0.1	NULL
ug	NULL
11g	NULL
30000	NULL
[	NULL
24h	NULL
48h	NULL
10000	NULL
|-€	NULL
[	NULL
D	NULL
S	NULL
&	NULL
Q	NULL
F	NULL
3	NULL
[	NULL
(	NULL
5	NULL
L	NULL
100	NULL
30	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Level	NULL
of	NULL
GM-CSF	NULL
produced	NULL
by	NULL
lipopolysaccharide	NULL
(	NULL
LPS	NULL
)	NULL
-activated	NULL
Rel~'~	NULL
peritoncal	NULL
macrophages	NULL
is	NULL
elevated	NULL
compared	NULL
with	NULL
normal	NULL
cells	NULL
.	NULL

Resident	NULL
peritoneal	NULL
macrophages	NULL
from	NULL
normal	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
or	NULL
Rel	NULL
~~	NULL
(	NULL
solid	NULL
bars	NULL
)	NULL
mice	NULL
were	NULL
stimulated	NULL
with	NULL
lipopolysaccharide	NULL
(	NULL
0.1	NULL
or	NULL
1	NULL
ug/ml	NULL
)	NULL
for	NULL
24	NULL
and	NULL
48	NULL
hr	NULL
.	NULL

Each	NULL
histogram	NULL
represents	NULL
the	NULL
mean	NULL
*	NULL
SE	NULL
from	NULL
four	NULL
or	NULL
six	NULL
experiments	NULL
.	NULL

the	NULL
IFN-y	NULL
CD28RE	NULL
differs	NULL
by	NULL
only	NULL
2	NULL
nucleotides	NULL
from	NULL
the	NULL
consensus	NULL
sequence	NULL
,	NULL
these	NULL
changes	NULL
reside	NULL
in	NULL
the	NULL
3	NULL
'	NULL
half-site	NULL
,	NULL
which	NULL
is	NULL
the	NULL
most	NULL
conserved	NULL
region	NULL
of	NULL
the	NULL
Rel	NULL
binding	NULL
element	NULL
(	NULL
39	NULL
)	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
ability	NULL
of	NULL
Rel	NULL
to	NULL
preferentially	NULL
bind	NULL
to	NULL
particular	NULL
CD28REs	NULL
may	NULL
account	NULL
for	NULL
the	NULL
relative	NULL
defects	NULL
in	NULL
expression	NULL
of	NULL
the	NULL
different	NULL
cytokine	NULL
genes	NULL
in	NULL
the	NULL
Rel~'~	NULL
T	NULL
cells	NULL
.	NULL

Despite	NULL
evidence	NULL
that	NULL
phorbol	NULL
ester	NULL
and	NULL
calcium	NULL
ionophore	NULL
treatment	NULL
mimics	NULL
activation	NULL
mediated	NULL
through	NULL
cross-linking	NULL
of	NULL
the	NULL
T-cell	NULL
receptor	NULL
and	NULL
CD28	NULL
costimulatory	NULL
receptor	NULL
(	NULL
18	NULL
)	NULL
,	NULL
the	NULL
relative	NULL
levels	NULL
of	NULL
IL-3	NULL
and	NULL
GM-CSF	NULL
produced	NULL
by	NULL
normal	NULL
and	NULL
Rel~'~-	NULL
T	NULL
cells	NULL
in	NULL
response	NULL
to	NULL
these	NULL
two	NULL
stimuli	NULL
differ	NULL
.	NULL

The	NULL
ability	NULL
of	NULL
PMA	NULL
and	NULL
ionomycin	NULL
to	NULL
induce	NULL
IL-2	NULL
(	NULL
19	NULL
)	NULL
,	NULL
IL-3	NULL
,	NULL
and	NULL
GM-CSF	NULL
,	NULL
albeit	NULL
several	NULL
fold	NULL
less	NULL
than	NULL
in	NULL
control	NULL
cells	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
Rel	NULL
,	NULL
may	NULL
indicate	NULL
that	NULL
in	NULL
T	NULL
cells	NULL
,	NULL
Rel	NULL
is	NULL
either	NULL
upstream	NULL
of	NULL
the	NULL
point	NULL
at	NULL
which	NULL
these	NULL
agents	NULL
engage	NULL
a	NULL
common	NULL
intracellular	NULL
pathway	NULL
required	NULL
for	NULL
the	NULL
transcription	NULL
of	NULL
these	NULL
genes	NULL
or	NULL
that	NULL
these	NULL
agents	NULL
operate	NULL
through	NULL
a	NULL
distinct	NULL
pathway	NULL
.	NULL

Alternatively	NULL
,	NULL
PMA	NULL
and	NULL
ionomycin	NULL
,	NULL
but	NULL
not	NULL
anti-CD3	NULL
plus	NULL
anti-CD28	NULL
costimulation	NULL
may	NULL
activate	NULL
other	NULL
Rel	NULL
family	NULL
proteins	NULL
or	NULL
different	NULL
transcription	NULL
factors	NULL
that	NULL
substitute	NULL
in	NULL
part	NULL
for	NULL
Rel	NULL
.	NULL

A	NULL
comparative	NULL
analysis	NULL
of	NULL
GM-CSF	NULL
production	NULL
by	NULL
mitogen-activated	NULL
Rel~'~	NULL
T	NULL
cells	NULL
and	NULL
macrophages	NULL
indicates	NULL
that	NULL
Rel	NULL
can	NULL
function	NULL
both	NULL
as	NULL
an	NULL
activator	NULL
or	NULL
repressor	NULL
of	NULL
gene	NULL
expression	NULL
.	NULL

While	NULL
this	NULL
dual	NULL
activity	NULL
is	NULL
well	NULL
established	NULL
for	NULL
the	NULL
Drosophila	NULL
Rel	NULL
homologue	NULL
Dorsal	NULL
(	NULL
40	NULL
,	NULL
41	NULL
)	NULL
,	NULL
the	NULL
results	NULL
presented	NULL
here	NULL
are	NULL
the	NULL
first	NULL
clear	NULL
demonstration	NULL
that	NULL
a	NULL
mammalian	NULL
GENE	NULL
CD28RE	NULL
SEQUENCE	NULL
LOCATION	NULL
IL-2	NULL
A	NULL
a	NULL
G	NULL
A	NULL
A	NULL
A	NULL
T	NULL
T	NULL
C	NULL
C	NULL
-163	NULL
to	NULL
-154	NULL
GM-CSF	NULL
A	NULL
G	NULL
G	NULL
A	NULL
G	NULL
A	NULL
T	NULL
T	NULL
C	NULL
C	NULL
-109	NULL
to	NULL
-98	NULL
IL-3	NULL
T	NULL
G	NULL
G	NULL
A	NULL
G	NULL
g	NULL
T	NULL
T	NULL
C	NULL
C	NULL
-116	NULL
to	NULL
-105	NULL
G-CSF	NULL
C	NULL
a	NULL
G	NULL
A	NULL
G	NULL
A	NULL
T	NULL
T	NULL
C	NULL
C	NULL
-193	NULL
to	NULL
-182	NULL
INF-y	NULL
A	NULL
G	NULL
G	NULL
A	NULL
A	NULL
A	NULL
c	NULL
T	NULL
Cot	NULL
-171	NULL
to	NULL
-160	NULL
Consensus	NULL
Rel	NULL
binding	NULL
motif	NULL
_	NULL
5'-N	NULL
G	NULL
G	NULL
N	NULL
N	NULL
A/T	NULL
T	NULL
T	NULL
C	NULL
C-3	NULL
'	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

-	NULL
Compilation	NULL
of	NULL
CD28	NULL
response	NULL
elements	NULL
in	NULL
the	NULL
promoters	NULL
of	NULL
murine	NULL
cytokine	NULL
genes	NULL
.	NULL

These	NULL
sequences	NULL
are	NULL
compared	NULL
with	NULL
the	NULL
consensus	NULL
Rel	NULL
binding	NULL
site	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
nonconserved	NULL
bases	NULL
are	NULL
shown	NULL
in	NULL
lowercase	NULL
.	NULL

Nucleotide	NULL
numbering	NULL
assigned	NULL
to	NULL
these	NULL
elements	NULL
in	NULL
the	NULL
5°	NULL
flanking	NULL
sequence	NULL
of	NULL
the	NULL
different	NULL
mouse	NULL
cytokine	NULL
genes	NULL
is	NULL
according	NULL
to	NULL
the	NULL
start	NULL
sites	NULL
of	NULL
transcription	NULL
.	NULL

Immunology	NULL
:	NULL
Gerondakis	NULL
et	NULL
al	NULL
.	NULL

Rel	NULL
protein	NULL
possesses	NULL
these	NULL
properties	NULL
.	NULL

One	NULL
plausible	NULL
model	NULL
that	NULL
could	NULL
explain	NULL
how	NULL
Rel	NULL
is	NULL
an	NULL
activator	NULL
of	NULL
GM-CSF	NULL
expression	NULL
in	NULL
T	NULL
cells	NULL
but	NULL
a	NULL
repressor	NULL
of	NULL
the	NULL
same	NULL
gene	NULL
in	NULL
macrophages	NULL
is	NULL
the	NULL
modulation	NULL
of	NULL
Rel	NULL
activity	NULL
through	NULL
interaction	NULL
with	NULL
different	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
two	NULL
cell	NULL
types	NULL
.	NULL

This	NULL
model	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
ability	NULL
of	NULL
Rel/NF-	NULL
«	NULL
B	NULL
proteins	NULL
to	NULL
associate	NULL
with	NULL
a	NULL
number	NULL
of	NULL
transcription	NULL
factors	NULL
including	NULL
ATF-2	NULL
(	NULL
42	NULL
)	NULL
,	NULL
SP1	NULL
(	NULL
43	NULL
)	NULL
,	NULL
and	NULL
the	NULL
C/EBP	NULL
proteins	NULL
(	NULL
44	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
described	NULL
here	NULL
could	NULL
result	NULL
from	NULL
Rel	NULL
associating	NULL
with	NULL
different	NULL
Rel-like	NULL
subunits	NULL
or	NULL
with	NULL
unrelated	NULL
proteins	NULL
.	NULL

For	NULL
exaniple	NULL
,	NULL
different	NULL
high	NULL
mobility	NULL
group	NULL
(	NULL
HMG	NULL
)	NULL
proteins	NULL
can	NULL
determine	NULL
whether	NULL
Rel/NF-	NULL
«	NULL
B	NULL
factors	NULL
function	NULL
as	NULL
activators	NULL
or	NULL
repres-sors	NULL
of	NULL
transcription	NULL
.	NULL

Binding	NULL
of	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
at	NULL
sites	NULL
adjacent	NULL
to	NULL
the	NULL
«	NULL
B	NULL
element	NULL
in	NULL
the	NULL
IFN-B	NULL
gene	NULL
augments	NULL
both	NULL
NF-	NULL
«	NULL
B	NULL
binding	NULL
and	NULL
transcriptional	NULL
activity	NULL
(	NULL
45	NULL
)	NULL
,	NULL
while	NULL
the	NULL
DSP1	NULL
HMG	NULL
protein	NULL
binds	NULL
to	NULL
a	NULL
negative	NULL
regulatory	NULL
element	NULL
flanking	NULL
the	NULL
IFN-B	NULL
«	NULL
B	NULL
site	NULL
and	NULL
converts	NULL
NF-	NULL
«	NULL
B	NULL
from	NULL
a	NULL
transcriptional	NULL
activator	NULL
to	NULL
a	NULL
repressor	NULL
(	NULL
46	NULL
)	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
genes	NULL
whose	NULL
expression	NULL
is	NULL
induced	NULL
or	NULL
repressed	NULL
by	NULL
Rel	NULL
should	NULL
provide	NULL
a	NULL
basis	NULL
for	NULL
elucidating	NULL
the	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
governing	NULL
the	NULL
transcription	NULL
regulatory	NULL
properties	NULL
of	NULL
Rel/NF-KB	NULL
factors	NULL
.	NULL

We	NULL
thank	NULL
Dr.	NULL
James	NULL
Allison	NULL
for	NULL
anti-CD28-producing	NULL
hybridoma	NULL
cells	NULL
;	NULL
Dr.	NULL
Jan	NULL
Allison	NULL
for	NULL
monoclonal	NULL
antibodies	NULL
to	NULL
CD44	NULL
,	NULL
CD4SRB	NULL
,	NULL
and	NULL
CD62	NULL
;	NULL
and	NULL
Dr.	NULL
Doug	NULL
Hilton	NULL
and	NULL
the	NULL
Cetus	NULL
Corporation	NULL
for	NULL
purified	NULL
murine	NULL
GM-CSF	NULL
and	NULL
IL-2	NULL
,	NULL
respectively	NULL
.	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
the	NULL
National	NULL
Health	NULL
and	NULL
Medical	NULL
Research	NULL
Council	NULL
(	NULL
Australia	NULL
)	NULL
,	NULL
Australian	NULL
Cooperative	NULL
Research	NULL
Centre	NULL
Grant	NULL
91007	NULL
,	NULL
and	NULL
a	NULL
Human	NULL
Frontiers	NULL
Science	NULL
Program	NULL
Grant	NULL
,	NULL
Principal	NULL
Investigator	NULL
,	NULL
Dr.	NULL
Diane	NULL
Mathis	NULL
.	NULL

A.S.	NULL
was	NULL
supported	NULL
by	NULL
fellowships	NULL
from	NULL
the	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
and	NULL
the	NULL
Swiss	NULL
National	NULL
Science	NULL
Foundation	NULL
.	NULL

1	NULL
.	NULL

-	NULL
Grilli	NULL
,	NULL
M.	NULL
,	NULL
Chiu	NULL
,	NULL
J.-S.	NULL
&	NULL
Lenardo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Int	NULL
.	NULL

Rev	NULL
.	NULL

Cytol	NULL
.	NULL

143	NULL
,	NULL
1-62	NULL
.	NULL

2	NULL
.	NULL

-	NULL
Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
Franzoso	NULL
,	NULL
G.	NULL
&	NULL
Brown	NULL
,	NULL
K.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

10	NULL
,	NULL
405-455	NULL
.	NULL

3	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1072	NULL
,	NULL
63-80	NULL
.	NULL

4	NULL
.	NULL

Nolan	NULL
,	NULL
G.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1992	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Genet	NULL
.	NULL

Dev	NULL
.	NULL

2	NULL
,	NULL
211-220.	NULL
.	NULL

5	NULL
.	NULL

Bacuerle	NULL
,	NULL
P.	NULL
A	NULL
.	NULL

&	NULL
Henkel	NULL
,	NULL
T.	NULL
(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

12	NULL
,	NULL
141-179	NULL
.	NULL

6	NULL
.	NULL

Finco	NULL
,	NULL
T.	NULL
S.	NULL
&	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Immunity	NULL
3	NULL
,	NULL
263-272	NULL
.	NULL

7	NULL
.	NULL

Brownell	NULL
,	NULL
E.	NULL
,	NULL
Mathieson	NULL
,	NULL
B.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Keller	NULL
,	NULL
J.	NULL
,	NULL
Ihle	NULL
,	NULL
J.	NULL
N.	NULL
&	NULL
Rice	NULL
,	NULL
N.	NULL
R	NULL
(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

7	NULL
,	NULL
1304	NULL
1309	NULL
.	NULL

8	NULL
.	NULL

Grumont	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

&	NULL
Gerondakis	NULL
,	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Oncogene	NULL
Res	NULL
.	NULL

2	NULL
,	NULL
245-254	NULL
.	NULL

9	NULL
.	NULL

Grumont	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

&	NULL
Gerondakis	NULL
,	NULL
S.	NULL
(	NULL
1994	NULL
)	NULL
Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

5	NULL
,	NULL
1321-1331	NULL
.	NULL

10	NULL
.	NULL

-	NULL
Liou	NULL
,	NULL
H.-C.	NULL
,	NULL
Sha	NULL
,	NULL
W.	NULL
C.	NULL
,	NULL
Scott	NULL
,	NULL
M.	NULL
L.	NULL
&	NULL
Baltimore	NULL
,	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
5249-5359	NULL
.	NULL

11	NULL
.	NULL

Miyamoto	NULL
,	NULL
S.	NULL
,	NULL
Schmitt	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

&	NULL
Verma	NULL
,	NULL
I.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91	NULL
,	NULL
5056-5060	NULL
.	NULL

12	NULL
.	NULL

-	NULL
Bryan	NULL
,	NULL
R	NULL
:	NULL
G.	NULL
,	NULL
Li	NULL
,	NULL
Y.	NULL
,	NULL
Lai	NULL
,	NULL
J.-H.	NULL
,	NULL
Van	NULL
,	NULL
M.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
,	NULL
Rich	NULL
,	NULL
R.	NULL
R.	NULL
&	NULL
Tan	NULL
,	NULL
T.-H.	NULL
(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
7933-7942	NULL
.	NULL

13	NULL
.	NULL

Venkataraman	NULL
,	NULL
L.	NULL
,	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

&	NULL
Sen	NULL
,	NULL
R.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181	NULL
,	NULL
1091-1099	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
,	NULL
40	NULL
.	NULL

A1	NULL
.	NULL

42	NULL
.	NULL

43	NULL
.	NULL

46	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93	NULL
(	NULL
1996	NULL
)	NULL
3409	NULL
Grumont	NULL
,	NULL
R.	NULL
J	NULL
.	NULL

&	NULL
Gerondakis	NULL
,	NULL
S.	NULL
(	NULL
1990	NULL
)	NULL
Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

1	NULL
,	NULL
345-350	NULL
.	NULL

Gilmore	NULL
,	NULL
T.	NULL
(	NULL
1991	NULL
)	NULL
Trends	NULL
Genet	NULL
.	NULL

7	NULL
,	NULL
318-322	NULL
.	NULL

Tan	NULL
,	NULL
T.-H.	NULL
,	NULL
Huang	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
A.	NULL
,	NULL
Longo	NULL
,	NULL
D.	NULL
L.	NULL
&	NULL
Rice	NULL
,	NULL
N.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4067-4075	NULL
.	NULL

Hoyos	NULL
,	NULL
B.	NULL
,	NULL
Ballard	NULL
,	NULL
D.	NULL
W.	NULL
,	NULL
Bohnlein	NULL
,	NULL
E.	NULL
,	NULL
Siekvitz	NULL
,	NULL
M.	NULL
&	NULL
Greene	NULL
,	NULL
W.	NULL
C.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
457-460	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Clipstone	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

63	NULL
,	NULL
1045-1083	NULL
.	NULL

Kontgen	NULL
,	NULL
F.	NULL
,	NULL
Grumont	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Strasser	NULL
,	NULL
A.	NULL
,	NULL
Metcalf	NULL
,	NULL
D.	NULL
,	NULL
Li	NULL
,	NULL
R.	NULL
,	NULL
Tarlinton	NULL
,	NULL
D.	NULL
&	NULL
Gerondakis	NULL
,	NULL
S.	NULL
(	NULL
1995	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

9	NULL
,	NULL
1965-1977	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
Irving	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
&	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
251	NULL
,	NULL
313—316	NULL
Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Tan	NULL
,	NULL
T.-H.	NULL
,	NULL
Rice	NULL
,	NULL
N.	NULL
,	NULL
Sica	NULL
,	NULL
A	NULL
.	NULL

&	NULL
Young	NULL
,	NULL
H.	NULL
A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
1696	NULL
1700	NULL
.	NULL

Shannon	NULL
,	NULL
M.	NULL
F.	NULL
,	NULL
Gamble	NULL
,	NULL
J.	NULL
R.	NULL
&	NULL
Vadas	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
85	NULL
,	NULL
674-678	NULL
,	NULL
Leo	NULL
,	NULL
O.	NULL
,	NULL
Foo	NULL
,	NULL
M.	NULL
,	NULL
Sachs	NULL
,	NULL
D	NULL
:	NULL
,	NULL
Samelson	NULL
,	NULL
L.	NULL
&	NULL
Bluestone	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
84	NULL
,	NULL
1374-1378	NULL
.	NULL

Harding	NULL
,	NULL
F.	NULL
A.	NULL
,	NULL
McArthur	NULL
,	NULL
J.	NULL
G.	NULL
,	NULL
Gross	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Raulet	NULL
,	NULL
D.	NULL
H.	NULL
&	NULL
Allison	NULL
,	NULL
J.	NULL
P.	NULL
(	NULL
1992	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
356	NULL
,	NULL
607-609	NULL
.	NULL

Strasser	NULL
,	NULL
A.	NULL
,	NULL
Harris	NULL
,	NULL
A.	NULL
W.	NULL
&	NULL
Cory	NULL
,	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
67	NULL
,	NULL
889-899	NULL
.	NULL

Metcalf	NULL
,	NULL
D.	NULL
(	NULL
1985	NULL
)	NULL
Blood	NULL
65	NULL
,	NULL
357-362	NULL
...	NULL
Kelso	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Immunol	NULL
.	NULL

145	NULL
,	NULL
2167-2176	NULL
.	NULL

Metcalf	NULL
,	NULL
D.	NULL
&	NULL
Rasko	NULL
,	NULL
J.	NULL
E.	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Leukemia	NULL
7	NULL
,	NULL
878-886	NULL
.	NULL

Croft	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

6	NULL
,	NULL
431-437	NULL
.	NULL

Sagerstrom	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Kerr	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Allison	NULL
,	NULL
J.	NULL
P.	NULL
&	NULL
Davis	NULL
,	NULL
M.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90	NULL
,	NULL
8987-8991	NULL
.	NULL

Trauth	NULL
,	NULL
B.	NULL
C.	NULL
,	NULL
Klas	NULL
,	NULL
C.	NULL
,	NULL
Peters	NULL
,	NULL
A.	NULL
M.	NULL
K.	NULL
,	NULL
Matzku	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
Moller	NULL
,	NULL
P.	NULL
,	NULL
Falk	NULL
,	NULL
W.	NULL
,	NULL
Debatin	NULL
,	NULL
K.-M.	NULL
&	NULL
Krammer	NULL
,	NULL
P.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
244	NULL
,	NULL
301-305	NULL
.	NULL

Itoh	NULL
,	NULL
N.	NULL
,	NULL
Yonehara	NULL
,	NULL
S.	NULL
,	NULL
Ishii	NULL
,	NULL
A.	NULL
,	NULL
Yonehara	NULL
,	NULL
M.	NULL
,	NULL
Mizushima	NULL
,	NULL
S.-I	NULL
.	NULL

,	NULL
Sameshima	NULL
,	NULL
M.	NULL
,	NULL
Hase	NULL
,	NULL
A.	NULL
,	NULL
Seto	NULL
,	NULL
Y	NULL
.	NULL

&	NULL
Nagata	NULL
,	NULL
S.	NULL
(	NULL
1991	NULL
)	NULL
Cell	NULL
66	NULL
,	NULL
233-243.	NULL
.	NULL

I	NULL
Kosaka	NULL
,	NULL
H.	NULL
,	NULL
Surh	NULL
,	NULL
C.	NULL
D.	NULL
&	NULL
Sprent	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
1291-1302	NULL
.	NULL

R	NULL
Thompson	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Kunkel	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Young	NULL
,	NULL
H.	NULL
,	NULL
Emerson	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
Leiden	NULL
,	NULL
J.	NULL
M.	NULL
&	NULL
June	NULL
,	NULL
C.	NULL
H.	NULL
(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
86	NULL
,	NULL
1333-1337	NULL
.	NULL

Rasko	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Gough	NULL
,	NULL
N.	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
The	NULL
Cytokines	NULL
Handbook	NULL
(	NULL
Academic	NULL
,	NULL
New	NULL
York	NULL
)	NULL
,	NULL
pp	NULL
.	NULL

343-369	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
243	NULL
,	NULL
355-361	NULL
.	NULL

Hrdlickova	NULL
,	NULL
R.	NULL
,	NULL
Nehyba	NULL
,	NULL
J	NULL
.	NULL

&	NULL
Humphries	NULL
,	NULL
E.	NULL
H.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Virol	NULL
.	NULL

68	NULL
,	NULL
308-319	NULL
.	NULL

Suzuki	NULL
,	NULL
N.	NULL
,	NULL
Matsunami	NULL
,	NULL
N.	NULL
,	NULL
Kanamori	NULL
,	NULL
H.	NULL
;	NULL
Ishida	NULL
,	NULL
N.	NULL
,	NULL
Shinizu	NULL
,	NULL
A.	NULL
,	NULL
Yaoita	NULL
,	NULL
Y.	NULL
,	NULL
Nikaido	NULL
,	NULL
T.	NULL
&	NULL
Honjo	NULL
,	NULL
T.	NULL
(	NULL
1988	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

262	NULL
,	NULL
5079-5086	NULL
.	NULL

Kunsch	NULL
,	NULL
C.	NULL
,	NULL
Ruben	NULL
,	NULL
S.	NULL
M.	NULL
&	NULL
Rosen	NULL
,	NULL
C.	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12	NULL
,	NULL
4412—4421	NULL
Anderson	NULL
,	NULL
K.	NULL
V.	NULL
(	NULL
1987	NULL
)	NULL
Trends	NULL
Genet	NULL
.	NULL

3	NULL
,	NULL
91-97	NULL
.	NULL

Levine	NULL
,	NULL
M.	NULL
(	NULL
1988	NULL
)	NULL
Cell	NULL
52	NULL
,	NULL
785-786	NULL
.	NULL

Kaszubska	NULL
,	NULL
W.	NULL
,	NULL
van	NULL
Huijsduijnen	NULL
,	NULL
R.	NULL
H.	NULL
,	NULL
Ghersa	NULL
,	NULL
P.	NULL
&	NULL
DeRaemy-Schenk	NULL
,	NULL
A.	NULL
M.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
7180-7190	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
Edwards	NULL
,	NULL
N.	NULL
L.	NULL
,	NULL
Duckett	NULL
,	NULL
C.	NULL
S.	NULL
&	NULL
Agranoff	NULL
,	NULL
A	NULL
.	NULL

B	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
EMBOJ	NULL
12	NULL
,	NULL
3551-3558	NULL
.	NULL

Stein	NULL
,	NULL
B	NULL
.	NULL

&	NULL
Baldwin	NULL
,	NULL
A.	NULL
S.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

13	NULL
,	NULL
7191-7198	NULL
.	NULL

Thanos	NULL
,	NULL
D.	NULL
&	NULL
Maniatis	NULL
,	NULL
T.	NULL
(	NULL
1992	NULL
)	NULL
Cell	NULL
71	NULL
,	NULL
777-789	NULL
.	NULL

Lehming	NULL
,	NULL
N.	NULL
,	NULL
Thanos	NULL
,	NULL
D.	NULL
,	NULL
Brickman	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
Ma	NULL
,	NULL
J.	NULL
,	NULL
Maniatis	NULL
,	NULL
T.	NULL
&	NULL
Ptashne	NULL
,	NULL
M.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
(	NULL
London	NULL
)	NULL
371	NULL
,	NULL
175-179	NULL
.	NULL

